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ABSTRACT 
Objective: To prepare Gemcitabine (GCB) loaded Methoxy Polyethylene Glycol-Poly (Caprolactone), (MPEG-PCL) nanoformulations and to carry out 
the physicochemical characterization. The primary objective of this research is to enhance the transport and penetration of drug across the blood-
brain barrier (BBB). 
Methods: Gemcitabine loaded MPEG-PCL nanoparticles were formulated by using modified nanoprecipitation method. Nanoformulations were 
prepared by varying drug: polymer ratio. The prepared nanoparticles (NP) were evaluated for particle size, zeta potential, entrapment efficiency, 
drug content and in-vitro drug release. The in vitro cytotoxicity of drug-loaded NPs was evaluated in U-87 MG cells.  
Results: The prepared nanoformulations indicated a significant increase in particle size with increase in the polymeric concentration. GCB loaded 
MPEG-PCL nanoformulation (GCBNP 3) exhibited a particle size of 223±1.4 nm. DSC thermo grams indicated that GCB was amorphously in in MPEG 
NPs. SEM, TEM, and AFM studies indicated that the NPs were spherical and smooth surface without any cracks or pinholes. In vitro release studies 
showed the GCBNP 3 shows an initial burst release followed by a more gradual and sustained-release phase (maximum drug release). The 
cytotoxicity of GCB loaded MPEG-PCL nanoformulations showed reduction in the IC50 value (4.1 µg). Apoptosis detection assay with Hoechst 33342 
dye was carried out and observed an increase in fluorescence in the apoptotic cells. By invasive studies, the GCB loaded MPEG-PCL nanoformulation 
inhibits the cell migration significantly when compared with the pure drug. 
Conclusion: The GCB loaded MPEG-PCL nanoparticles indicated improved cytotoxic activity with minimal concentrations compared with the pure 
drug in U-87 MG glial cells. Hence, it can be concluded that GCB loaded MPEG-PCL nanoformulation can serve as a potential drug delivery tool for 
the treatment of brain tumours. 
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INTRODUCTION 
Cancer remains one of the most deadly diseases in the world. In 
spite of advancements for diagnosis and treatment, cancer is still a 
big threat to our society. This is the second most common disease 
after cardiovascular disorders for maximum deaths in the world [1]. 
Although not very frequent, brain tumours contribute significantly 
to morbidity, often affect children and overall have a poor prognosis. 
Due to marked resistance to radiation and chemotherapy, the 
prognosis for patients with glioblastomas is very poor. Many genetic 
alterations involve in the development of nervous tissue tumours 
have been identified and may lead to novel therapeutic approaches 
[2]. The brain is one of the least accessible organs of the body, thus 
making the delivery of neurotherapeutics a challenge. Despite its 
relatively high nutrient support and exchange requirements, the 
uptake of any compound is strictly regulated by the blood-brain 
barrier (BBB). The Conventional drug delivery systems which 
release the drug into general circulation fail to deliver drugs 
effectively to the brain and are therefore not very useful in treating 
certain diseases that affect CNS. Therefore, there is a need to develop 
and design approaches which specifically target to brain in a better 
and effective way [3]. The targeted delivery of nonmaterial’s can 
overcome difficulties associated with conventional free anticancer 
drugs, including insolubility under aqueous conditions, rapid 
clearance, and a lack of selectivity, resulting in nonspecific toxicity 
toward normal cells and lower the dose of drugs delivered to the 
cancer cells [4].  
Colloidal drug carriers such as nano particles (NPs) have been used 
to overcome the BBB and to improve the transport of drugs across it 
[5-8]. The major advantage of these colloidal drug carrier systems is 
their possibility of the drug targeting by modifying the distribution 
of drugs in the body [9]. Brain-targeted polymeric nanoparticles 
have been found to increase the therapeutic efficacy and reduce the 
toxicity of a large number of drugs. By coating the NPs with 
surfactants, higher concentrations of drugs can be delivered to the 
brain [10]. NPs can accumulate in tumours after systemic 
administration, and their biodistribution is largely determined by their 
physical and biochemical properties such as particle size, nature of the 
polymer and drug, and surface biochemical properties [11].  
The use of polymeric nanoparticles (PNP) in drug delivery, generally 
increase the stability of the pharmaceutical agents and it can be easily 
and cheaply fabricated in large quantities by a multitude of methods. 
Additionally, the use of absorbable or degradable polymers provides a 
high degree of biocompatibility for PNP delivery system [12]. 
GCB is a nucleoside analogue that despite its efficient antitumor 
activity, suffers from several drawbacks including a very short 
plasma half-life, thus generating the need to use high doses, 
simultaneously leading to severe dose-limiting side effects [13]. GCB 
is reported to possess a very modest potency to penetrate the blood-
brain barrier (BBB) [14]. Further, GCB is reported to possess poor 
prognosis in the very common malignant brain tumor, glioblastoma 
multiforme [15]. The detailed literature survey indicates the need 
for investigation of GCB loaded drug carriers targeting the brain. 
Hence, GCB loaded MPEG-PCL nanoparticles were designed to 
deliver GCB across BBB and target brain tumor. Polymeric nano 
formulation is prepared to enhance the transport efficiency across 
BBB and to target the brain glioma cells. The cytotoxicity and 
cellular uptake of the drug-loaded NPs were evaluated in vitro.  
MATERIALS AND METHODS 
MPEG-PCL and Pluronic F-127 were purchased from Sigma-Aldrich 
(St. Louis, MO, USA), GCB was obtained as a gift sample from Strides 
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Pharmaceuticals, acetone (analytical grade) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA), Phosphate buffered saline, (3-
[4,5-dimethylthiazol-2-yl] 2,5-diphenyl tetrazolium bromide) and 
dimethyl sulfoxide were purchased from Sigma-Aldrich (St. Louis, 
MO, USA), Hoechst 33342 (Sigma B-2262), and all the other solvents 
used are analytical grade. The U-87MG glial cells were obtained from 
National Centre for Cell Science (NCCS), Pune, India.  
Differential scanning calorimetry analysis (DSC) 
Differential scanning calorimetric (DSC) analysis were carried out by 
using Shimadzu DSC-60, to determine the interaction between the 
GCB and other excipients used. Samples were analyzed in a 
temperature range of 0 °C-400 °C at a heating rate of 5 °C/min under 
nitrogen atmosphere. The samples were prepared by pressing them 
in a DSC aluminium pans and subjected to analysis.  
Preparation of drug loaded nanoparticles 
Nanoparticles of MPEG-PCL containing GCB were prepared by using 
the modified nanoprecipitation method [16]. Accurately weighed the 
amount of MPEG-PCL and GCB were dissolved in 5 ml of acetone. 10 
ml of 1% Pluronic F-127 in phosphate buffer 9 was added to the 
polymeric solution and stirred continuously for 2 h at 500 rpm using 
a magnetic stirrer.  
The obtained nanoparticular suspension was centrifuged at 11,000 
rpm in cooling centrifuge (Remi) and the supernatant was collected, 
lyophilized and stored at 4 °C. Repeated the procedure by varying in 
the polymeric concentration to optimize the formulations and were 
coded as GCBNP 1, GCBNP 2, GCBNP 3 and GCBNP 4. A blank 
nanoformulation (PNP) was prepared by the same procedure, but 
excluding GCB. The details of the formula are given in the table 1. 
 
Table 1: Various formulations of GCB loaded MPEG-PCL nanoformulations 
S. No. Ingredients GCBNP 1 GCBNP 2 GCBNP 3 GCBNP 4 PNP 
1 Gemcitabine 10 mg 10 mg 10 mg 10 mg - 
2 MPEG-PCL 10 mg 20 mg 30 mg 40 mg 10 mg 
3 Pluronic F 127 1 % (10 ml) 1 % (10 ml) 1 % (10 ml) 1 % (10 ml) 1%(10 ml) 
4 Acetone 5 ml 5 ml 5 ml 5 ml 5 ml 
 
Characterization of GCB loaded MPEG-PCL nanoparticles 
Particle size  
The size of the prepared nanoparticles was analyzed by using 
Photon Correlation Spectroscopy (PCS). All samples were diluted 
with ultra-purified water, and the analysis was performed at a 
scattering angle of 90 °C and at a temperature of 25 °C [17]. The 
mean diameter for each sample and mean hydrodynamic diameter 
was generated by cumulative analysis in triplicate.  
Zeta potential  
The zeta potential of the prepared nanoformulations was 
determined by using a Zetasizer. The measurements were 
performed using an aqueous dip cell in an automatic mode by 
placing diluted samples in the capillary measurement cell, and cell 
position is adjusted. The electrical charge on the nanoparticles was 
measured by using particle electrophoresis (Zetasizer Zen Systems 
3600, Malvern Instruments Ltd., UK) after they had been diluted 
with deionized water to avoid multiple scattering effects and then 
placed in a folded capillary cell (25 °C). Measurements were made in 
triplicate, and the results are shown with mean±standard error. 
Surface morphology 
Scanning electron microscopy (SEM) 
The prepared nanoparticles were observed under a scanning 
electron microscope to study the particle diameter and dispersion 
pattern. The equipment used was Quanta 200 FEG scanning electron 
microscope (FEI Quanta FEG 200). The NPs were dispersed in water 
and drop coated on aluminium stub using double-sided carbon tape. 
The sample was then coated with gold sputter coating unit at 10 Pa 
vacuum for 10 S (SC7620, Japan). The typical acceleration potential 
used was 30 kV and the image was captured at the desired 
magnification. 
Transmission electron microscopy (TEM) 
The surface morphology of the particles was studied by using 
transmission electron microscopy set with 200 kV by placing an air 
dried nanoparticular suspension on copper electron microscopy 
grids.  
Atomic force microscopy (AFM)  
Nanoformulation was characterized by using atomic force 
microscope (XEI 70, Park system, Korea). The analysis was carried 
out by running the machine in the non-contact tapping mode. The 
samples were drop coated on glass substrates. The nanoparticles 
were characterized by observing the patterns that appeared on the 
surface topography and analyzing the AFM data. The topological 3D 
image was obtained in tapping mode at a resonance frequency of 
272.98 kHz. 
Drug content 
Drug content was determined by taking 1 ml of the GCB loaded 
MPEG-PCL nanosuspension. To this nanosuspension, 1 ml of 
aqueous potassium dihydrogen phosphate solution (30 mM) was 
added and the mixture was centrifuged with 33,000g at 15 °C. The 
clear supernatant was removed and analysed spectrophoto-
mertically and drug content was calculated. 
Percentage entrapment efficiency  
The entrapment efficiency of the drug-loaded nanoparticles was 
carried out by centrifuging specified amount of nanosuspension at 
13000 xg and the supernatant was assayed for free drug 
concentration by spectrophotometric method [18]. Entrapment 
efficiency was calculated as follows:  
 
In vitro release studies 
The in vitro release profile of the prepared nanoparticular drug 
delivery system was studied by diffusion across an artificial 
membrane. In the donor compartment nanosuspension containing 
known concentration of drug was placed and in the receptor 
compartment buffer was placed and constantly agitated using a 
magnetic stirrer at 37 °C. Samples were withdrawn from the 
receptor compartment for estimation of released drug and replaced 
with similar volume of buffer. The experiment was carried out in 
triplicate, and the values are reported as mean value±standard 
deviation. 
Cell culture and maintenance  
U-87 MG cells were obtained from National centre for cell science 
(NCCS), Pune, India. The cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS) and 1% 
penicillin-streptomycin (PS) in a humidified incubator under the 
conditions of 37 °C and 5% CO2. 
MTT assay 
The cells were plated separately in 96 well plates at a concentration 
of 1 × 105 cells/well [15]. After 24 h, cells were washed twice with 
100 µl of serum-free medium and starved for an hour at 37 °C. After 
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starvation, cells were treated with the test material for 24 h. At the 
end of the treatment period, the medium was aspirated and serum 
free medium containing MTT (0.5 mg/ml) was added and incubated 
for 4 h at 37 °C in a CO2 incubator. The MTT containing medium was 
then discarded, and the cells were washed with PBS (200 µl). The 
crystals were then dissolved by adding 100 µl of DMSO and this was 
mixed properly by pipetting up and down. The absorbance of the 
purple, blue formazan dye was measured spectrophotometrically in 
a microplate reader at 570 nm (Biorad 680).  
Cellular uptake of drug loaded nano particles (Hoechst dye) 
For a qualitative study using laser scanning fluorescence 
microscope, U-87 MG cells were seeded onto 48-well plates with 
glass coverslips at a density of 50,000 cells per well, incubated for 24 
h, and treated with GCBNP 3, PNF and pure drug at a concentration 
of 200 mg/ml for 4 h. The cells were then washed with PBS and fixed 
using 4% formaldehyde at room temperature for 15 min. 
Subsequently, the cells were washed with PBS for three times and 
stained with Hoechst dye (1 mg/ml) for 30 min. The cells were 
washed with PBS for three times before the coverslips were 
mounted onto microscope slides and visualized using an Olympus 
fluorescence microscope, and the images were quantified [18]. 
Migration assay: (Blood-brain barrier) 
U-87 MG cells were grown to 80% confluence then serum starved 
overnight before setting up the experiment. Cells were washed twice 
in Dulbecco’s PBS and harvested from the plate using 0.5 mol/l 
EDTA (pH 6.8). The cells were collected and re-suspended in 
starvation medium. We used 24-well trans well chambers (BD Bio 
coat Control Inserts from BD Biosciences) with 8.0-Am pore size 
polycarbonate membrane for this experiment. The cells were plated 
at a density of 5 X 104 per well in 0.5 µl in the upper well, which was 
placed into a lower well containing one of the following conditions: 
complete medium+drug at different concentrations or complete 
growth medium (10% FBS). After 24 h at 37°C, 5% CO2 incubator for 
24 h, the experiment was stopped by wiping the cells from the well 
with a cotton swab and fixed and stained using the Diff-Quik kit 
(Dade-Behring). Migration was quantities by counting 12 fields at a 
magnification of 400. Each experiment was repeated in triplicate and 
the results were averaged. Statistical analysis was done using the 
Student’s t-test.  
Invasion assay  
The invasion assay was identical to the above migration assay except 
that inserts were coated with 100 AL Matrigel (BD Bioscience) 
diluted to 1 mg/µl. The experiment was stopped after 72 h using the 
same method as described above. 
RESULTS 
DSC is an important technique to analyze the polymer-drug 
interactions and also it has previously been used to show the 
dispersity of the molecules [20]. Thermal analysis was used to 
evaluate the changes in thermodynamic properties that occur when 
the material supplied heat energy. Changes that can be observed in 
the process of melting, desolvation, recrystallization and solid phase 
transformations indicated by endothermic or exothermic peaks at 
thermogram. DSC thermogram showed solid endothermic peak of 
GCB at 277.62 °C. The polymer MPEG-PCL indicated endothermic 
peaks at 48.31 °C and 58.30 °C, respectively. The endothermic peaks 
of GCB and MPEG-PCL observed at similar temperature ranges, 
which eliminate the possibility of any physical interaction. The DSC 
thermo grams of GCB and MPEG-PCL and their combinations are 
shown in fig. 1 A, B, C. 
Particle size 
It is well known that the sizes of particles are highly dependent on 
the preparation method and conditions employed. It is generally 
accepted that an increase in the percentage of the polymer leads to 
increase in particle size. The particle size of the nanoformulation is 
an important property of particles that not only does it affect 
endocytosis by tumour cells but also influences its accumulation in 
tumour tissue via EPR effect. It determines in vivo drug release 
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Fig. 1: Differential scanning thermogram of (A) GCB (B) MPEG-
PCL (C) Physical mixture of GCB, MPEG-PCL 
 
Also, they can also influence the drug loading, drug release and 
stability of drug inside NPs [21]. In this study the mean particle size 
of GCB loaded nanoparticles is significant to plain nanoformulation 
and the average size of nanoparticles is illustrated in fig. 1 A and B. 
The electrostatic repulsion between particles with the same electric 
charge prevents the aggregation of the particles [22]. It has been 
demonstrated that the anionic surface of drug delivery system 
would provide improved blood compatibility as compared to the 
cationic carrier. The zeta potential value of the plain nanoparticles 
and GCB loaded nanoparticles were recorded. 
  
Sathesh et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 83-90 
86 
Table 2: Particle size and zeta potential for GCB loaded MPEG-PCL nanoformulations 
Code Particle size (nm)# Zeta potential (mV)# 
GCB NP 1 214±1.6 -29±1.7 
GCB NP 2 236±2.1 -28±2.3 
GCB NP 3 223±1.4 -26±1.4 
GCB NP 4 269±2.3 -28±1.8 
PNP 241±1.8 -21±1.2 




Fig. 2: Particle size and size distribution of (A) Plain NP (B) GCB NP 3 
 
SEM analysis 
SEM analysis of the GCBNP 3 indicated that the particles are isolated, 
and it was clear that the particles were spherical in shape, and 
hollow in structure, with a large central cavity in which GCB was 
loaded as shown in fig. 3. 
 
 
Fig. 3: SEM image of GCBNP 3 nanoparticles 
 
TEM analysis 
The representative TEM photomicrograph of the GCBNP 3 was 
shown in fig. 4. The photomicrographs of the formulation suggested 




Fig. 4: TEM image of GCBNP 3 nanoparticles 
AFM analysis 
AFM technique has been widely applied to produce surface-
dependent information in three dimensions on the nanometer scale. 
It is capable of resolving surface details down to the atomic level and 
can give morphological images in high resolution. The 3D AFM 
topographies and phase contrast of the GCBNP 3 nanoparticles was 
illustrated in fig. 5, AFM investigation clearly substantiates that, the 
non-existence of complex topography of the nanoparticle surface, 
which confirms no major micro-caves and pores rather than simply 
being smooth as shown in the conventional SEM images, and smooth 
surface without any cracks (or) pinholes. 
 
 
Fig. 5: AFM image of GCBNP 3 nanoparticles 
 
Drug content and entrapment efficiency  
The prepared GCB loaded MPEG-PCL nanoformulations were 
examined for drug content and maximum amount drug was loaded 
in the GCB NP 3(0.381 µg/ml). The drug content of all the batches is 
represented in the fig. 6. 
GCB loaded MPEG-PCL nanoformulations were estimated for 
entrapment efficienciency, and the results are shown in the fig.7. 
Among the prepared batches of the nanoparticles, maximum 
entrapment of drug was observed in GCBNP 3 (84.64%). 
In vitro drug release 
The in vitro release of GCB loaded MPEG-PCL NPs in buffered 
solution pH 7.4 was shown in fig. 8. A typical two-phase-release 
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was observed, i.e., burst release was observed from all the four 
batches of GCB loaded MPEG-PCL NPs in 1 hr, followed by a 
relatively slower and sustained release was observed up to 24 h. 
The GCBNP 3 shows the maximum drug release by the end of the 
24th hour. 
 
Fig. 6: Average drug content of GCB loaded MPEG-PCL 
nanoparticles 
#Values indicated are mean±standard error mean of three trials 
 
 
Fig. 7: Entrapment efficiency of GCB loaded MPEG-PCL 
nanoparticles 
#Values indicated aremean±standard error mean of three trials 
 
After 24 h, GCB was released at a slower rate. The release rate of 
GCB was also slower due to the presence of the external MPEGPCL 
coating, which effectively delayed its release from the nanoparticles. 
The sustained release of GCB is highly beneficial in enhancing long-
term anticancer efficiency and improving drug accumulation at the 
targeted site. 
MTT assay 
In this study, the MTT cell viability assay was carried out to 
determine the cytotoxicity of GCB loaded MPEG-PCL nano-
formulations (GCBNP 3) in human glial cells (U-87 MG cells). 
Graphical representation of % cell viability of cells was shown in the 
fig.9. The fluorescence images were observed, and the images are 
shown in the fig.10. GCB loaded MPEG-PCL nano formulations 
showed a reduction of the IC50 value (4.1µg/ml) when compared to 
the pure drug (6.7µg/ml). The plain NPs had not shown any 
significant cytotoxicity. 
 
#Values indicated aremean±standard error mean of three trials 
Fig. 8: In vitro drug release of GCB loaded MPEG-PCL 
nanoparticles in pH 7.4 
 
 
Fig. 9: Percentage of cell viability of pure drug, PNP and GCBNP 3 
#Values indicated aremean±standard error mean of three trials 
 
Hoescht staining 
The U-87 MG Cells were treated by GCB loaded with MPEG-PCL 
nanoformulation (GCBNP 3) which shows maximum intracellular 
accumulation. The cellular uptake of GCB loaded MPEG-PCL 
nanoparticles in U-87 MG cells were examined under fluorescence 
microscopy and the images are shown in fig.11.  
The results showed significant apoptotic cell death in GCB loaded 
MPPEGPCL nanoformulation compared with the pure drug. This 
indicates that the nanoformulation penetrates the cell membrane of 
glial cells. 
Cell migration 
In this study, the U-87 MG cells were examined for the effect of 
drug on cellular migration and the results are illustrated in the 
following fig 12. The GCB loaded MPEG-PCL nanoformulation 
(GCBNP 3) treatment resulted in a significant inhibition of cell 
migration. 
Invasion assay 
The GCB loaded MPEG-PCL nanoformulation (GCBNP 3) showed a 
significant drop in the ability to migrate into the empty space 
compared with control in U-87 MG cells and the number of cells 
crossed matrigel in the drug treatment was significant decreased 
compared to the control cells.  
Invasion images of the plain drug, PNP and GCBNP 3 in U-87 MG cell 
lines are shown in fig. 13. 
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Pure drug-1 µl pure drug-2 µl pure drug-5 µl pure drug-10 µl 
    
PNF 1 µl PNF 2 µl PNF 5 µl PNF 10 µl 
    
GCB NP3 1 µl GCB NP3 2 µl GCB NP3 5 µl GCB NP3 10 µl 
    
Fig. 10: Images of U-87 MG Cells treated with control and various concentrations of control, pure drug, plain nanoformulation (PNF) and 
GCBNP 3 nanoformulation 
 
Control Pure drug PNF GCB NP3 
    
Fig. 11: Comparison of penetration of control, pure drug, PNP and GCBNP 3 in U-87 MG cell lines using Hoechst 33342 DNA staining technique 
 
 
Fig. 12: Inhibition of cell migration by control, pure drug, PNP and GCBNP 3 in U-87 MG cell lines 
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Control Pure drug PNP GCB NP 
    
Fig. 13: Invasion images of U-87 MG cell lines by control, pure drug PNP and GCBNP 3 
 
DISCUSSION 
The therapeutic efficacy of chemotherapeutic agents in the 
treatment of malignant brain glioma was poor due to low drug 
penetration and accumulation within the tumor. Nanoparticle-
mediated therapy may be especially helpful for the treatment of the 
disseminated and very aggressive brain tumors. Biodegradable 
materials are natural or synthetic in origin and are degraded invivo, 
either enzymatically or non-enzymatically or both, to produce 
biocompatible, toxicologically safe by-products which are further 
eliminated by the normal metabolic pathways [24, 25]. A number of 
studies showed that MPEGylated poly cyanoacrylate nanoparticles 
penetrated into the brain to a larger extent [26, 27]. Moreover, drug-
loaded nanoparticles released their content immediately and 
showed a pharmacological effect in no more than 60 min after their 
administration [28]. Nanoprecipitation is a simple method used for 
encapsulation of both hydrophilic and hydrophobic drugs in 
nanoparticles [29]. A modified nanoprecipitation method utilizes use 
a co-solvent to either increase the entrapment efficiency of the drug 
in nanoparticles or to reduce the mean particle size of the 
nanoparticles. 
Gemcitabine hydrochloride, a widely used cytotoxic agent, was used 
a model drug to prove the efficiency of the polymeric nanoparticles 
to transport the drug across the blood-brain barrier. GCB is reported 
to possess a very modest potency to penetrate the blood-brain 
barrier (BBB)[14]. Further, GCB is reported to possess poor 
prognosis in the very common malignant brain tumor, glioblastoma 
multiforme. 
In this study, the GCB loaded MPEG-PCL nanoformulations were 
successfully prepared by modified nanoprecipitation method for 
effective brain glioma treatment. The optimized formulation showed 
the particle size around 269±2.3 nm, such high zeta potential helps 
the particles to repel each other and to prevent aggregation leading 
to colloidal stability [30], with an ideal drug loading coefficient and 
encapsulation ratio. 
The GCBNP3 nanoformulation was further analyzed in human glial 
cell lines (U 87 MG) for MTT assay, cellular uptake, invasion, cell 
migration and flow cytometry. The IC50 value of pure drug, plain 
nanoformulation and GCBNP3 was found to be 6.7µg,>100 µg, 4.1 µg 
GCBNP3 nanoformulation which showed that, improved in the 
reduction of the IC50 value of GCBNP3 nanoformulation. The plain 
NPs did not show any cytotoxicity in which cell viability of more 
than 60% was achieved in U-87 cells. By the cellular uptake of 
GCBNP3 in glial cells, confirmed that significant apoptotic cell death 
when compared to control cells. The effect of drug on cellular 
migration in U-87 cells shows significant inhibition of cell migration 
by GCBNP3 nanoformulation.  
CONCLUSION 
Gemcitabine hydrochloride loaded polymeric nanoparticles were 
designed, optimized and prepared by modified nanoprecipitation 
method. The physicochemical characterization of the 
nanoformulations indicated that the prepared nanoparticles were 
consistent and stable. In this study, Gemcitabine is selected as a 
model drug and other anticancer agents can also be tried in the same 
nanoparticular platform for delivery into the brain. The nano-
formulations are designed for sustained release of the drug for a 
period of 24 h and this may reduce the frequency of dosing, thereby 
minimizing the occurrence of side effects. The in-vitro studies 
carried out on U-87 MG cell lines suggests reduced toxicity to normal 
cells and increase cellular uptake. Hence, it can be concluded that 
GCB loaded MPEG-PCL nanoformulation can serve as a potential 
formulation for the treatment of brain tumors. But more animal 
studies and extensive clinical studies are needed to check and 
confirm the efficacy of the prepared drug delivery system. 
ACKNOWLEDGEMENT 
The Ph.D merit scholarship awarded by Vels Institute of Science 
Technology and Advanced Studies (VISTAS), Vels University, 
Pallavaram, Chennai, India, to one of the authors, Mr. B. V. Nagarjuna 
Yadav has been gratefully acknowledged. 
CONFLICT OF INTERESTS 
Declared None 
REFERENCES 
1. Imran Ali, Waseem A, Wani, Kishwar Saleem. Cancer scenario 
in india with future perspectives. Cancer Ther 2011;8:56-70. 
2. Balkrishna B Yeole. Trends in the brain cancer incidence in 
india. Asian Pacific J Cancer Prev 2008;9:267-70. 
3. M Intakhab Alam, Sarwar Beg, Abdus Samad, Sanjula Baboota, 
Kanchan Kohli, Javed Ali, et al. Strategy for effective brain drug 
delivery. Eur J Pharm Sci 2010;40:385-403. 
4. Mi Kyung Yu, Jinho Park, Sangyong Jon. Targeting strategies for 
multifunctional nanoparticles in cancer imaging and therapy. 
Theranostics 2012;2:3-44. 
5. K Michaelis, MM Hoffmann, S Dreis, E Herbert, RN Alyautdin, M 
Michaelis, et al. Covalent linkage of apolipoprotein e to albumin 
nanoparticles strongly enhances drug transport into the brain. J 
Pharmacol Exp Ther 2006;317:1246-53. 
6. RN Aliautdin, J Kreuter, DA Kharkevich. Drug delivery to the 
brain with nanoparticles. Eksp Klin Farmakol 2003;66:65-8. 
7. J Kreuter. Nanoparticulate systems for brain delivery of drugs. 
Adv Drug Delivery Rev 2001;47:65-81. 
8. WM Pardridge. Intravenous non-viral RNAi gene therapy of 
brain cancer. Expert Opin Biol Ther 2004;4:1103-13. 
9. Y Zhang, WM Pardridge. Delivery of beta-galactosidase to 
mouse brain via the blood–brain barrier transferrin receptor. J 
Pharmacol Exp Ther 2005;313:1075-81. 
10. Dimple Chopra, Monica Gulati, Vikrant Saluja, Purnima Pathak, 
Parikshit Bansal. Brain permeable nanoparticles, recent 
patents on CNS. Drug Discovery 2008;3:216-25. 
11. Avgoustakis K. Pegylated poly (lactide) and poly (lactide–co–
glycolide) nanoparticles, preparation, properties and possible 
application in drug delivery. Curr Drug Delivery 2004;1:321–33. 
12. K Bhaskar Reddy, V Vaijayanthi, S Brito Raj, E Mohanambal, R 
Charulatha, Y Madhusudan Rao. Nanoparticles for brain 
targeting. Indian J Novel Drug Delivery 2011;3:91-7.  
13. Viacheslav Chubenko, Aleksandr Nikolaevich Stukov, Olesya 
Belyaeva, Vladimir Bespalov, Fedor Vladimirovich Moiseenko, 
Valentina Lukyanchikova, et al. Therapeutic effect of 
gemcitabine on experimental tumors of the brain. J Clin Oncol 
2013;31:e13005. 
14. J Sigmond, RJ Honeywell, TJ Postma, CMF Driven, SM de Lange, 
K van der Born, et al. Gemcitabine uptake in glioblastoma 
Sathesh et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 83-90 
90 
multiforme: potential as a radiosensitizer. Ann Oncol 2009; 
20:182-7. 
15. Reddy LH, Couvreur P. Novel approaches to deliver 
Gemcitabine to cancers. Curr Pharm Des 2008;14:1124-37. 
16. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine loaded PLGA 
and PBCA nanoparticles: preparation, optimization, 
Characterization, in vitro and pharmacodynamic studies. Eur J 
Pharm Biopharm 2010;76:189-99. 
17. Archana Mehrotra, Jayanta K Pandit. Critical process parameters 
evaluation of modified nanoprecipitation method on lomustine 
nanoparticles and cytostatic activity study on L132 human 
cancer cell line. J Nanomedic Nanotechnol 2012;3:1-8. 
18. K Elkharraz, N Faisant, C Gusec, F Siepmann, B Arica-Yegin, JM 
Oger, et al. Paclitaxel-loaded microparticles and implants for the 
treatment of brain cancer: Preparation and physicochemical 
characterization. Int J Pharm 2006;314:127-36. 
19. Yanna Cui, Qingxing Xu, Pierce Kah-Hoe Chow, Deping Wang, 
Chi-Hwa Wang. Transferrin-conjugated magnetic silica PLGA 
nanoparticles loaded with doxorubicin and paclitaxel for brain 
glioma treatment. Biomaterials 2013;34:8511-20. 
20. Bhavna, Shadab Md, Mushir Ali, Sanjula Baboota, Jasjeet Kaur 
Sahni, Aseem Bhatnaga, et al. Preparation, characterization, in 
vivo biodistribution and pharmacokinetic studies of donepezil-
loaded PLGA nanoparticles for brain targeting. Drug Dev Ind 
Pharm 2014;40:278-87. 
21. Eerikainen H, Kauppine EI. Preparation of polymeric 
nanoparticles containing corticosteroid by a novel aerosol flow 
reactor method. Int J Pharm 2003;263:69-83. 
22. Mohanraj VJ, Chen Y. Nanoparticles: a review. Trop J Pharm Res 
2006;5:561-73. 
23. Fernandez CA, Baumhover NJ, Duskey JT, Khargharia S, Kizzire 
K, Ericson MD. Metabolically stabilized long-circulating 
PEGylated poly acridine peptide polyplexes mediate 
hydrodynamically stimulated gene expression in liver. Gene 
Ther 2011;18:23-37. 
24. Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C, 
Klein C, et al. Quantification and localization of PEGylated poly 
cyanoacrylate nanoparticles in the brain and spinal cord during 
experimental allergic encephalomyelitis in the rat. Eur J 
Neurosci 2002;15:1317-26.  
25. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. 
Polymeric systems for controlled drug release. Chem Rev 
1999;99:3181-98. 
26. Nair LS, Laurencin CT. Biodegradable polymers as biomaterials. 
Prog Polym Sci 2007;32:762-98. 
27. Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, 
et al. D, A phase II study of paclitaxel in patients with recurrent 
malignant glioma using different doses depending upon the 
concomitant use of anticonvulsants: a North American brain 
tumor consortium report. Cancer 2001;91:417-22. 
28. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, 
Kreuter J. Delivery of loperamide across the blood–brain 
barrier with polysorbate 80-coated poly butyl cyanoacrylate 
nanoparticles. Pharm Res 1997;14:325–8. 
29. Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation 
of hydrophilic and lipophilic drugs in PLGA nanoparticles by the 
nanoprecipitation method. Drug Dev Ind Pharm 1999;25:471-6.  
30. Vandana M, Sahoo SK. Optimization of physicochemical 
parameters influencing the fabrication of protein-loaded 
chitosan nanoparticles. Nanomed 2009;4:773-85. 
 
